

Recent Progress and Emerging Trends in Taste Masking Strategies for Oral Drug Delivery

Murali Krishna Prasad Vallabhaneni^{1*}, Venkata Srikanth Meka²

¹ Navinta III Inc, Boca Raton, FL, USA 33487

² Rising Pharma Specialities Pvt Ltd, Hyderabad, India, 500019

*Corresponding Author: Murali Krishna Prasad Vallabhaneni, Navinta III Inc, Boca Raton, FL, USA 33487.

Email: [Murali.krishna@navinta.com]

Abstract

Taste masking remains a critical challenge in pharmaceutical formulation development, particularly for pediatric and geriatric populations where medication adherence is significantly impacted by palatability. This comprehensive review examines the latest advances in taste masking technologies for drug products, encompassing both traditional approaches and innovative emerging techniques. We discuss physical barriers including coating technologies and complexation methods, chemical modifications through prodrug design, organoleptic approaches using flavoring systems, and novel technologies such as 3D printing and nanotechnology-based solutions. The review provides detailed analysis of each technology with mechanistic insights, formulation considerations, and recent applications. A comprehensive compilation of commercially approved taste-masked products demonstrates successful implementation of these technologies. The future perspective highlights the integration of artificial intelligence in taste prediction and formulation optimization, personalized medicine approaches based on genetic variations in taste perception, and sustainable taste masking solutions using natural biomaterials. This review serves as a comprehensive resource for pharmaceutical scientists involved in developing palatable drug formulations.

Keywords: Taste masking, pharmaceutical formulations, coating technology, complexation, prodrugs, pediatric formulations, patient compliance, drug delivery

1. Introduction

The unpleasant taste of active pharmaceutical ingredients (APIs) represents a significant barrier to patient compliance, with studies indicating substantial medication non-adherence in pediatric and adult populations due to taste issues [1]. The global market for taste-masked pharmaceutical products has experienced remarkable growth, driven by increasing focus on patient-centric drug development and regulatory emphasis on pediatric formulation requirements [2].

Taste perception involves complex interactions between drug molecules and taste receptors, primarily bitter taste receptors (T2Rs), which recognize a wide range of pharmaceutical compounds [3]. The human genome encodes 25 functional bitter taste receptors (TAS2Rs), capable of recognizing thousands of bitter compounds through promiscuous binding patterns [4]. The challenge is compounded by the fact that many APIs possess inherently bitter, metallic, or astringent tastes due to their molecular structures, particularly those containing nitrogen heterocycles, aromatic rings, and specific functional groups associated with pharmacological activity [5].

Recent advances in understanding taste physiology at the molecular level have revealed that bitter taste transduction involves G-protein coupled receptor activation, phospholipase C- β 2 signaling, and transient receptor potential channel M5 (TRPM5) activation [6]. This knowledge, coupled with innovations in

pharmaceutical technology, has led to sophisticated approaches for taste masking that go beyond traditional flavoring methods.

2. Mechanisms of Taste Perception and Drug-Induced Taste

2.1 Molecular Basis of Pharmaceutical Bitterness

Recent crystallographic and computational studies have identified key structural features of APIs that contribute to bitter taste [7]. The primary molecular determinants include presence of basic nitrogen atoms with pKa values greater than 7, aromatic ring systems with electron-withdrawing substituents, hydrophobic regions in molecules with molecular weight exceeding 300 Da, and specific pharmacophores including guanidine, thiourea, and quinoline moieties [8]. Structure-activity relationship studies have demonstrated that even minor structural modifications can significantly alter taste perception, providing opportunities for rational design of less bitter drug molecules.




Fig 1: Schematic representation of Taste masking mechanism

2.2 Taste Transduction Pathways and Blocking Mechanisms

The canonical bitter taste pathway involves binding of bitter compounds to TAS2Rs, leading to activation of the heterotrimeric G-protein gustducin [9]. This triggers a cascade involving phospholipase C- β 2, inositol trisphosphate production, and calcium release from intracellular stores, ultimately resulting in neurotransmitter release. Understanding these pathways has enabled development of targeted approaches to taste masking at different intervention points, including receptor antagonism, signal transduction interference, and competitive inhibition strategies.

Table 1: Mechanisms of Taste Masking Technologies

Technology Category	Mechanism of Action	Examples	Advantages	Limitations
Physical Barriers	Prevents drug-receptor contact	Polymer coating, Microencapsulation	Complete taste masking	Increased dosage form size
Molecular Complexation	Molecular entrapment	Cyclodextrins, Ion exchange resins	Reversible, stable	Limited drug loading

Chemical Modification	Alters molecular structure	Prodrugs, Salt forms	Eliminates bitter moiety	Requires metabolic activation
Sensory Modification	Competes/blocks perception	Flavors, Cooling agents	Simple implementation	May not mask completely
Nanotechnology	Nano-scale encapsulation	NLCs, Polymeric nanoparticles	High efficiency	Complex manufacturing

3. Physical Barrier Technologies

3.1 Advanced Coating Systems

3.1.1 pH-Responsive Polymeric Coatings

pH-sensitive polymers represent a sophisticated approach to taste masking, utilizing the principle of ionization-dependent solubility [10]. Methacrylic acid copolymers such as Eudragit E PO exhibit unique pH-dependent solubility profiles, remaining insoluble at salivary pH (6.8-7.4) while dissolving rapidly at gastric pH below 5.0. The mechanism involves protonation of dimethylamino groups in acidic conditions, leading to polymer dissolution and drug release. Recent innovations include development of interpolymer complexes that provide enhanced stability and taste masking efficiency. Kollicoat Smartseal 30D, a methyl methacrylate and diethylaminoethyl methacrylate copolymer, offers additional advantages of aqueous processing and reduced coating levels while maintaining effective taste masking. Process optimization studies have demonstrated that coating levels of 5-10% w/w typically achieve complete taste masking for highly bitter drugs like clarithromycin and levofloxacin. The selection of plasticizers significantly impacts coating performance, with triethyl citrate and polyethylene glycol showing optimal flexibility and taste barrier properties.

3.1.2 Lipid-Based Coating Technologies

Lipid coating technologies have evolved significantly with the introduction of structured lipid systems that combine different melting point lipids for optimized release profiles [11]. Hot-melt coating processes utilize lipids such as glyceryl behenate (Compritol 888 ATO) and glyceryl palmitostearate (Precirol ATO 5) to create hydrophobic barriers around drug particles. The taste masking mechanism involves prevention of drug dissolution in saliva through the hydrophobic lipid barrier, which subsequently disperses or melts in the gastrointestinal tract. Recent advances include development of self-emulsifying lipid coatings that enhance bioavailability while maintaining taste masking properties. These systems incorporate surfactants and co-surfactants within the lipid matrix, forming fine emulsions upon contact with aqueous media. Solid lipid nanoparticle coatings applied through fluidized bed processing represent another innovation, offering uniform nanoscale coating with minimal weight gain. Process parameters such as spray rate, atomization pressure, and bed temperature critically influence coating efficiency and taste masking effectiveness.

3.1.3 Reverse Enteric Coating

Reverse enteric coating represents an innovative inversion of traditional enteric coating principles, using polymers soluble at neutral pH but insoluble in acidic conditions [12]. Aminoalkyl methacrylate copolymers such as Eudragit EPO and Kollicoat Smartseal demonstrate this behavior through pH-dependent ionization of amino groups. At salivary pH, these polymers remain unionized and insoluble, preventing drug release and taste perception. Upon reaching the acidic gastric environment, protonation of amino groups leads to polymer dissolution and drug release. This approach offers advantages over traditional coatings by ensuring immediate drug availability for absorption while maintaining taste masking in the oral cavity. Recent formulation strategies combine reverse enteric polymers with pore formers to modulate release kinetics without compromising taste masking. Application techniques including spray coating in conventional pans, fluid bed coating, and compression coating have been successfully employed for various dosage forms.

3.2 Microencapsulation Technologies

3.2.1 Coacervation Techniques

Coacervation involves phase separation of polymer solutions to form a polymer-rich phase that deposits around drug particles, creating microcapsules with excellent taste masking properties [13]. Complex coacervation using oppositely charged polyelectrolytes such as chitosan-alginate or gelatin-acacia systems provides robust encapsulation through electrostatic interactions. The process parameters including polymer concentration, pH, temperature, and stirring rate significantly influence microcapsule characteristics and taste masking efficiency. Recent advances incorporate enzymatic crosslinking using transglutaminase or tyrosinase to improve microcapsule stability and prevent premature drug release. The addition of taste masking agents such as cyclodextrins or ion exchange resins within the coacervate matrix provides dual-mechanism taste masking. Optimization studies have demonstrated that core-to-wall ratios between 1:1 and 1:2 typically achieve optimal taste masking while maintaining acceptable drug loading. Scale-up considerations include maintenance of hydrodynamic conditions and temperature control to ensure reproducible microcapsule properties.

3.2.2 Fluid Bed Coating and Wurster Processing

Fluid bed coating technology, particularly Wurster processing, enables precise application of taste masking coatings to particles ranging from 50 μm to 2 mm [14]. The Wurster column creates a controlled particle circulation pattern, ensuring uniform coating distribution through repeated passes through the spray zone. Recent technological advances include implementation of electrostatic coating assistance, which improves coating efficiency and reduces agglomeration through charge repulsion. Multi-layer coating systems incorporating functional layers for taste masking, moisture protection, and controlled release have been successfully developed. In-line process analytical technology (PAT) tools including near-infrared spectroscopy and Raman spectroscopy enable real-time monitoring of coating thickness and uniformity. Critical process parameters include inlet air temperature, spray rate, atomization pressure, and fluidization velocity, which must be optimized based on particle size distribution and coating polymer properties. Recent innovations in nozzle design and air distribution plates have improved coating efficiency and reduced process time.

3.2.3 Spray Drying and Spray Congealing

Spray drying technology for taste masking has evolved to include sophisticated approaches such as co-spray drying with taste masking excipients and production of hollow microspheres [15]. The mechanism involves rapid evaporation of solvent from atomized droplets, leading to particle formation with drug embedded within a taste masking matrix. Selection of carrier materials significantly impacts taste masking effectiveness, with polymers like hydroxypropyl methylcellulose phthalate and polyvinylacetal diethylaminoacetate showing excellent performance. Process optimization using design of experiments has identified critical parameters including inlet temperature (120-180°C), feed rate, and atomization pressure that influence particle size, morphology, and taste masking properties. Spray congealing, utilizing molten lipids or waxes as coating materials, offers advantages of solvent-free processing and immediate solidification upon cooling. Recent developments include incorporation of volatile flavoring agents through post-spray drying absorption, where porous particles absorb flavor oils to enhance palatability. Scale-up strategies focus on maintaining similar droplet size distribution and drying kinetics between laboratory and production scales.

4. Complexation and Molecular Inclusion

4.1 Cyclodextrin Complexation

Cyclodextrins form inclusion complexes with drug molecules through their hydrophobic cavity, effectively sequestering bitter-tasting moieties from taste receptors [16]. Beyond traditional β -cyclodextrin, modified derivatives offer enhanced taste masking capabilities through improved complex stability constants.

Sulfobutylether- β -cyclodextrin (Captisol®) provides superior complexation for basic drugs through additional electrostatic interactions between the sulfonate groups and protonated amines. Hydroxypropyl- β -cyclodextrin demonstrates enhanced aqueous solubility and reduced renal toxicity compared to parent β -cyclodextrin, making it suitable for oral formulations. The complexation process can be optimized through various methods including kneading, co-precipitation, spray drying, and freeze drying, with each method influencing complex stability and taste masking efficiency. Recent studies have demonstrated the utility of ternary complexes incorporating polymers (PVP, HPMC) or surfactants (poloxamer, SLS) as auxiliary agents to enhance complex stability through formation of non-inclusion complexes. Molecular modeling studies using density functional theory and molecular dynamics simulations provide insights into host-guest interactions and guide selection of appropriate cyclodextrin derivatives. Phase solubility studies according to Higuchi and Connors classification help determine stoichiometry and stability constants of drug-cyclodextrin complexes.




Fig 2: Cyclodextrin complexation

4.2 Ion Exchange Resin Complexation

Ion exchange resins provide robust taste masking through ionic binding of drug molecules to the polymer matrix, preventing their interaction with taste receptors [17]. Strong cation exchange resins such as Amberlite IRP69 (sodium polystyrene sulfonate) and Kyron T-114 (potassium polystyrene sulfonate) effectively complex basic drugs through sulfonic acid functional groups. The drug loading process involves equilibrium partitioning influenced by factors including pH, ionic strength, temperature, and drug-to-resin ratio. Optimization studies have established that drug loading at pH 5-6 for basic drugs typically achieves maximum binding capacity while maintaining stability. Weak cation exchange resins containing carboxylic acid groups offer pH-dependent drug release, providing additional control over taste masking and drug release profiles. Recent innovations include surface modification of resins with taste masking polymers such as ethylcellulose or Eudragit to provide dual-barrier taste masking. Particle size reduction of resin-drug complexes through jet milling or high-pressure homogenization improves mouthfeel and enables incorporation into various dosage forms. Characterization techniques including differential scanning calorimetry, X-ray diffraction, and infrared spectroscopy confirm complex formation and stability.




Fig 3: Ion Exchange resin for the taste masking

4.3 Metal Coordination Complexes

Metal coordination complexes represent an underutilized but effective approach for taste masking, particularly for drugs containing electron-donating groups capable of coordinating with metal ions [18]. Zinc and magnesium ions, being GRAS substances, form stable coordination complexes with quinolone antibiotics, macrolides, and tetracyclines through interaction with carbonyl and hydroxyl groups. The taste masking mechanism involves alteration of the drug's electronic structure and reduction of its interaction with bitter taste receptors. Complex formation typically occurs at metal-to-drug molar ratios between 1:1 and 1:2, depending on the number of coordination sites available. Solution chemistry studies using Job's plot method and mole ratio method help determine complex stoichiometry and formation constants. The stability of these complexes in simulated salivary fluid ensures taste masking, while dissociation in acidic gastric conditions allows drug release and absorption. Recent research has explored mixed-ligand complexes incorporating amino acids or organic acids as co-ligands to enhance complex stability and palatability. Solid-state characterization reveals that many metal-drug complexes exist as amorphous or nanocrystalline forms, potentially offering improved dissolution rates.

Table 2: Complexation Technologies for Taste Masking

Complex Type	Drug Types	Loading Capacity	Release pH	Commercial Examples
β -Cyclodextrin	Hydrophobic drugs	1:1 to 1:2 molar	pH independent	Nicorette® gum
HP- β -Cyclodextrin	Various	1:1 to 1:3 molar	pH independent	Sporanox® solution
Cation exchange resin	Basic drugs	100-200 mg/g	pH > 6	Tussionex® suspension
Anion exchange resin	Acidic drugs	50-150 mg/g	pH < 5	Fosrenol® tablets
Metal complexes	Antibiotics	1:1 to 1:2 molar	pH < 4	Experimental formulations

5. Chemical Modification Approaches

5.1 Prodrug Design for Taste Masking

Prodrug design for taste masking involves strategic modification of drug molecules to eliminate structural features responsible for bitter taste while maintaining therapeutic efficacy following biotransformation [19]. Ester prodrugs of carboxylic acid-containing drugs effectively mask taste by eliminating ionic interactions with taste receptors. Successful examples include valacyclovir (L-valyl ester of acyclovir), which demonstrates significantly improved palatability compared to the parent drug. Phosphate prodrugs offer dual advantages of improved aqueous solubility and taste masking, as demonstrated by fosamprenavir and

fosphenytoin. The design process considers enzymatic stability in the oral cavity to prevent premature drug release and taste perception. Amino acid conjugates exploit peptide transporters for absorption while providing taste masking through zwitterionic character at physiological pH. Recent innovations include self-immolative linker strategies that ensure predictable and complete drug release following enzymatic or chemical triggering. Computational approaches using quantitative structure-taste relationship (QSTR) models guide prodrug design by predicting taste profiles based on molecular descriptors. Stability studies in simulated salivary fluid and gastric fluid ensure appropriate taste masking and drug release characteristics.

5.2 Salt Formation and Crystalline Modifications

Selection of appropriate salt forms significantly impacts drug taste through modification of physicochemical properties including solubility, dissolution rate, and crystal structure [20]. Organic salt forms such as citrates, gluconates, and lactates often exhibit better taste profiles compared to mineral acid salts due to their inherent flavor characteristics and buffering capacity. The taste improvement mechanism involves reduced dissolution rate in saliva, altered drug partitioning, and potential complexation between the drug and counterion. Screening studies evaluate multiple salt forms using parameters including taste assessment, stability, hygroscopicity, and bioavailability. Co-crystallization with GRAS coformers such as saccharin, nicotinamide, and caffeine provides an alternative approach to modify taste without forming ionic salts. The co-crystal design process considers complementary functional groups capable of forming robust supramolecular synthons through hydrogen bonding. Amorphous solid dispersions with taste masking polymers combine taste improvement with potential bioavailability enhancement for poorly soluble drugs. Hot-melt extrusion and spray drying represent scalable manufacturing approaches for preparing these systems. Characterization using solid-state NMR, terahertz spectroscopy, and pair distribution function analysis provides insights into molecular-level interactions.

6. Organoleptic Modification Systems

6.1 Advanced Flavoring Systems

Modern flavoring approaches integrate multiple strategies beyond simple addition of sweeteners and flavors to create comprehensive taste masking systems [21]. Flavor encapsulation technologies including spray drying, fluid bed coating, and coacervation enable controlled release of flavoring agents during consumption. This temporal flavor release masks residual bitterness while providing pleasant sensory experience throughout the dosing period. Synergistic flavor combinations based on sensory science principles exploit perceptual interactions between different taste modalities. For instance, certain fruit flavors combined with cooling agents effectively mask bitter taste through cross-modal sensory interactions. Natural flavor enhancers derived from plant sources, including steviol glycosides, monk fruit extracts, and thaumatin, provide intense sweetness without caloric content. Recent research has identified flavor compounds that specifically suppress bitter taste perception through allosteric modulation of T2R receptors. Microencapsulated flavor systems using modified starches or maltodextrins as carriers ensure flavor stability during storage while providing immediate release upon administration. The optimization of flavoring systems employs response surface methodology to identify optimal combinations of multiple flavoring agents.

6.2 Taste Receptor Antagonists

Direct blocking of bitter taste receptors using small molecule antagonists represents a sophisticated approach to taste masking at the molecular level [22]. GIV3616, a selective antagonist of multiple T2R receptors, effectively reduces perception of bitter pharmaceuticals when co-formulated. Probenecid and its analogs demonstrate broad-spectrum T2R antagonism through competitive inhibition at the orthosteric binding site. Structure-activity relationship studies have identified key pharmacophores required for T2R antagonism, guiding development of new antagonists. Peptide-based taste modifiers derived from natural sources, including certain plant proteins and milk proteins, show promise as biocompatible taste masking agents. These peptides function through multiple mechanisms including receptor antagonism, signal transduction

interference, and formation of protective layers on taste buds. High-throughput screening using calcium imaging assays enables rapid identification of novel T2R antagonists from chemical libraries. Computational docking studies using homology models of T2R structures facilitate rational design of receptor-specific antagonists. Safety evaluation of taste receptor antagonists considers potential off-target effects and systemic exposure following oral administration.

6.3 Sensory Modification Techniques

Sensory modification techniques exploit neurophysiological mechanisms of taste perception to reduce bitter taste through alternative sensory inputs [23]. Cooling agents such as menthol, WS-3 (N-ethyl-p-menthane-3-carboxamide), and WS-23 activate TRPM8 receptors, providing sensory distraction that reduces bitter taste perception. The cooling sensation effectively masks unpleasant taste through competitive neural processing and altered attention to taste stimuli. Effervescent systems combining citric acid and sodium bicarbonate create carbon dioxide bubbles that provide tactile stimulation while facilitating rapid drug dispersion. This mechanical action reduces drug concentration at taste receptor sites and provides pleasant tingling sensation. Textural modifications using mouth-coating agents such as povidone, hydroxypropyl cellulose, and sodium alginate create protective films that reduce drug contact with taste receptors. These polymers form viscous solutions that coat the oral cavity, providing physical barrier and lubrication. Incorporation of numbing agents like benzocaine at sub-anesthetic concentrations provides localized taste bud desensitization without affecting overall oral sensation. Multi-sensory approaches combining visual cues (color), olfactory stimuli (aroma), and auditory feedback (effervescence) enhance overall palatability through cross-modal sensory integration.

7. Novel and Emerging Technologies

7.1 3D Printing for Taste-Masked Formulations

Three-dimensional printing technologies enable unprecedented control over drug distribution and taste masking layer architecture in pharmaceutical dosage forms [24]. Fused deposition modeling (FDM) allows creation of tablets with drug-containing cores surrounded by taste masking polymer shells of precise thickness. The layer-by-layer construction permits incorporation of multiple materials with different functionalities, including immediate release drug compartments and extended taste masking barriers. Selective laser sintering (SLS) technology has been employed to create porous structures that facilitate rapid disintegration while maintaining taste masking through polymer coating of drug particles. Binder jetting techniques enable preparation of orally disintegrating tablets with taste masked drug particles distributed within a rapidly dissolving matrix. Recent advances in multi-material printing allow simultaneous deposition of drug, taste masking polymers, and flavoring agents in predetermined spatial arrangements. Personalized dosing with integrated taste masking becomes feasible through adjustment of printing parameters to achieve desired drug loading while maintaining consistent taste masking layer thickness. Digital light processing (DLP) technology offers high resolution printing of taste masked dosage forms with complex geometries optimized for pediatric administration. Process optimization considers factors including printing temperature, layer height, infill density, and post-processing conditions that influence taste masking effectiveness.




Fig 4: 3D Printing for Taste masking formulations

7.2 Nanotechnology-Based Approaches

7.2.1 Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers represent second-generation lipid nanoparticles that provide superior taste masking through their unique internal structure [25]. The incorporation of liquid lipids within solid lipid matrices creates imperfections that accommodate higher drug loading while preventing crystallization. These nanocarriers effectively encapsulate bitter drugs within their lipid core, preventing contact with taste receptors while maintaining stability in the oral cavity. Production methods including high-pressure homogenization, microemulsion technique, and solvent emulsification-evaporation have been optimized for taste masking applications. Surface modification with polyethylene glycol or poloxamer enhances stability and prevents aggregation in saliva. Recent innovations include development of mucoadhesive NLCs that provide prolonged residence time in the oral cavity without drug release, ensuring complete taste masking. The selection of lipid components significantly influences taste masking efficiency, with combinations of glyceryl behenate and medium-chain triglycerides showing optimal performance. Characterization using photon correlation spectroscopy, atomic force microscopy, and differential scanning calorimetry confirms nanoparticle structure and drug encapsulation.

7.2.2 Polymeric Nanoparticles

Polymeric nanoparticles offer versatile platforms for taste masking through encapsulation of drugs within biocompatible polymer matrices [26]. PLGA nanoparticles prepared by nanoprecipitation or emulsion-solvent evaporation methods provide effective taste masking while ensuring complete drug release in the gastrointestinal tract. Chitosan nanoparticles exploit the polymer's mucoadhesive properties and ability to form polyelectrolyte complexes with anionic drugs. Layer-by-layer assembly techniques enable creation of multi-layered nanoparticles with alternating polymer coatings that provide robust taste masking barriers. Recent developments include stimuli-responsive polymeric nanoparticles that remain stable at salivary pH but rapidly release drug in response to gastric pH or enzymes. Surface functionalization with taste masking molecules such as cyclodextrins or flavoring agents provides additional taste improvement. The incorporation

of polymeric nanoparticles into various dosage forms including tablets, suspensions, and orally disintegrating films has been successfully demonstrated. Quality control considerations include particle size distribution, zeta potential, drug loading efficiency, and in vitro drug release profiles.

7.2.3 Nanofibers and Nanocomposites

Electrospun nanofibers provide unique advantages for taste masking through their high surface area and ability to incorporate multiple functional components [27]. The electrospinning process enables encapsulation of bitter drugs within polymer nanofibers that dissolve rapidly while preventing direct drug-taste receptor interaction. Coaxial electrospinning produces core-shell nanofibers with drug in the core and taste masking polymer in the shell, providing effective barrier properties. Recent innovations include development of multilayered nanofiber mats with different layers serving distinct functions such as taste masking, flavor release, and drug delivery. Nanocomposite systems incorporating drug-loaded nanoparticles within electrospun fibers provide dual-level taste masking through particle encapsulation and fiber entrapment. The selection of polymers for nanofiber production considers factors including electrospinnability, taste masking efficiency, and dissolution characteristics. Post-processing techniques including crosslinking and coating can further enhance taste masking properties and mechanical stability. Applications include development of fast-dissolving oral films and orally disintegrating tablets with superior palatability.

7.3 Orally Disintegrating Technologies

Advanced orally disintegrating tablet (ODT) platforms integrate sophisticated taste masking strategies to address the challenge of drug exposure in the oral cavity [28]. Zydis® freeze-dried technology incorporates drug-cyclodextrin or drug-ion exchange resin complexes within a rapidly dissolving matrix of gelatin and mannitol. The freeze-drying process creates a highly porous structure that disintegrates within seconds while taste masked drug complexes prevent bitter taste perception. OraSolv® and DuraSolv® technologies utilize compression of taste masked drug particles with effervescent disintegration agents and specific compression techniques that maintain coating integrity. WOWTAB® (Without Water Tablet) technology combines taste masked granules prepared by spray drying or fluid bed coating with specially processed saccharides that provide rapid disintegration and pleasant mouthfeel. Recent innovations include incorporation of superdisintegrants such as croscopovidone and sodium starch glycolate at optimized concentrations to achieve disintegration times below 30 seconds. The use of co-processed excipients specifically designed for ODT applications provides improved compressibility while maintaining rapid disintegration. Critical quality attributes include disintegration time, taste assessment, mechanical strength, and friability, which must be balanced through formulation and process optimization.

7.4 Buccal and Sublingual Delivery Systems

Buccal and sublingual delivery systems require sophisticated taste masking due to extended contact time with taste receptors during drug absorption [29]. Mucoadhesive films incorporate taste masking layers that prevent drug release on the taste-sensitive dorsal tongue surface while allowing absorption through the ventral tongue or buccal mucosa. Multi-layered film designs include a drug-containing layer, taste masking barrier layer, and backing layer that controls directional drug release. Buccal patches utilize reservoir systems where drug is contained within a taste impermeable membrane with controlled release through the mucosal-contacting surface. Recent developments include incorporation of permeation enhancers such as sodium lauryl sulfate and dimethyl sulfoxide that facilitate drug absorption without compromising taste masking. Sublingual tablets employ rapidly dissolving taste masking coatings that provide initial protection followed by drug release for absorption. In situ gelling systems using thermosensitive or pH-sensitive polymers form taste masking gels upon administration that gradually release drug for mucosal absorption. Characterization methods include ex vivo permeation studies using porcine buccal mucosa, mucoadhesion testing, and residence time evaluation.

8. Evaluation Methods for Taste-Masked Formulations

8.1 In Vivo Human Panel Studies

Human sensory evaluation remains the gold standard for assessing taste masking effectiveness, employing validated protocols with trained or untrained panels depending on study objectives [30]. Time-intensity studies track taste perception dynamically, providing valuable information about onset, duration, and intensity of bitter taste breakthrough. Modern approaches incorporate facial coding analysis using computer vision algorithms to objectively quantify facial expressions associated with bitter taste perception. Physiological measurements including heart rate variability, skin conductance, and salivary flow rate provide additional objective markers of taste response. Statistical analysis using appropriate methods such as ANOVA, principal component analysis, and preference mapping enables robust interpretation of sensory data. Recent innovations include use of functional magnetic resonance imaging (fMRI) to visualize brain activation patterns in response to taste stimuli, providing insights into neural processing of pharmaceutical taste.

8.2 Electronic Tongue Technology

Electronic tongue systems employ arrays of chemical sensors combined with pattern recognition algorithms to provide objective assessment of taste [31]. Recent advances incorporate biomimetic sensors containing actual taste receptor proteins or cells that respond to bitter compounds similarly to human taste buds. Machine learning algorithms including artificial neural networks, support vector machines, and deep learning models enable prediction of human taste perception from sensor responses. Multichannel taste sensor systems such as the ASTREE e-tongue and TS-5000Z utilize potentiometric measurements across multiple lipid membrane sensors to generate taste fingerprints. Calibration using standard bitter compounds and correlation with human panel data validates electronic tongue measurements for specific drug products. Integration of electronic tongue data with formulation parameters through multivariate analysis facilitates optimization of taste masking formulations.

8.3 In Vitro Dissolution and Release Studies

Biomimetic dissolution apparatus simulating oral cavity conditions provides crucial information about drug release and potential taste exposure [32]. Flow-through cell methods using simulated salivary fluid at physiological temperature and flow rates assess taste masking barrier effectiveness. Novel dissolution methods incorporate taste sensor probes that continuously monitor bitter compound concentrations during dissolution testing. Fiber optic dissolution testing enables real-time monitoring of drug release without sampling, providing high temporal resolution data. Mathematical modeling using Weibull, Higuchi, and Korsmeyer-Peppas equations describes drug release kinetics and predicts taste masking duration. Correlation between in vitro dissolution profiles and in vivo taste perception guides development of biorelevant dissolution specifications.

Table 3: FDA-Approved and Commercially Available Taste-Masked Drug Products (2019-2024)

Product Name	Active Ingredient	Taste Masking Technology	Dosage Form	Manufacturer	Year
Katerzia®	Amlodipine	Suspension technology	Oral suspension	Azurity	2019
Tosymra®	Sumatriptan	Buffer system	Nasal spray	Promius	2019
Qmiiz ODT®	Meloxicam	Complexation	ODT	CLR	2020
Azstarys®	d-MPH/serdexmethylphenidate	Prodrug	Capsule	Corium	2021
Nurtec ODT®	Rimegepant	Taste masking coating	ODT	Biohaven	2021
Lybalvi®	Olanzapine/samidorphan	Film coating	Tablet	Alkermes	2021
Relyvrio®	Sodium phenylbutyrate/taurursodiol	Flavoring/suspension	Powder	Amylyx	2022
Camzyos®	Mavacamten	Capsule formulation	Capsule	BMS	2022
Cibinqo®	Abrocitinib	Film coating	Tablet	Pfizer	2022
Voxzogo®	Vosoritide	Injection formulation	Injection	BioMarin	2022
Daybue®	Trofinetide	Flavoring system	Oral solution	Acadia	2023
Augtyro®	Repotrectinib	Particle coating	Capsule	Turning Point	2023
Ojjaara®	Momelotinib	Film coating	Tablet	GSK	2023
Joenja®	Leniolisib	Coating	Tablet	Pharming	2023
Vyjuvek®	B-VEC	Gene therapy formulation	Topical gel	Krystal	2023
Rezdiffra®	Resmetirom	Coating technology	Tablet	Madrigal	2024
Cobenfy®	Xanomeline/trospium	Salt selection	Capsule	BMS	2024

9. Future Perspectives and Emerging Trends

9.1 Artificial Intelligence and Machine Learning Applications

The integration of artificial intelligence (AI) and machine learning (ML) in taste masking represents a paradigm shift in formulation development [33]. Deep learning models trained on molecular structures and taste perception data can predict drug bitterness with increasing accuracy, enabling early identification of taste masking requirements during drug discovery. Quantitative structure-taste relationship (QSTR) models incorporating molecular descriptors, quantum chemical calculations, and pharmacophore mapping provide insights into structural modifications that reduce bitter taste. Neural networks analyze complex relationships between formulation variables and taste masking effectiveness, identifying optimal combinations that might not be apparent through traditional approaches.

Generative AI models can propose novel taste masking excipients and coating polymers by learning from existing pharmaceutical databases. Computer vision algorithms analyzing facial expressions and tongue movements during taste assessment provide objective, reproducible data that supplements traditional sensory evaluation. Natural language processing of patent literature and scientific publications identifies emerging taste masking technologies and predicts future trends. Digital twin technology creates virtual models of taste-masked formulations, enabling in silico optimization before physical prototyping. Reinforcement learning algorithms optimize coating processes in real-time, adjusting parameters based on continuous quality measurements.

9.2 Personalized Medicine and Pharmacogenomics

Genetic variations in taste receptor genes (TAS2R) significantly influence individual perception of pharmaceutical bitterness, with certain polymorphisms resulting in "super-tasters" who experience intense bitter taste [34]. Pharmacogenomic testing can identify patients requiring enhanced taste masking or alternative formulation approaches. Population-specific taste preferences driven by genetic and cultural factors necessitate development of region-specific taste masking strategies. Age-related changes in taste perception, from heightened sensitivity in children to diminished taste in elderly patients, require age-appropriate taste masking approaches.

Personalized compounding using 3D printing technology enables preparation of individually optimized taste-masked medications based on patient genetic profiles and preferences. Digital health platforms collecting patient feedback on medication palatability create databases for improving future formulations. Precision medicine approaches consider drug-gene interactions that might influence both therapeutic response and taste perception. Development of taste receptor expression profiles for different patient populations guides selection of appropriate taste masking strategies.

9.3 Sustainable and Bio-Based Technologies

Environmental sustainability drives development of biodegradable taste masking materials derived from renewable sources [35]. Plant-based polymers including modified celluloses, starches, and proteins offer eco-friendly alternatives to synthetic coating materials. Natural taste modifiers extracted from miracle fruit (miraculin), gymnema sylvestre (gymnemic acids), and other botanical sources provide sustainable taste masking options. Fermentation-derived compounds produced by engineered microorganisms offer scalable, renewable sources of taste masking agents.

Green chemistry principles guide selection of solvents and processing methods, with aqueous coating systems replacing organic solvents. Waste valorization strategies convert pharmaceutical industry byproducts into functional taste masking excipients. Life cycle assessment of taste masking technologies evaluates environmental impact from raw material sourcing through end-of-life disposal. Circular economy approaches design taste-masked formulations for recyclability and minimal environmental persistence. Biotechnology-derived polymers such as polyhydroxyalkanoates and bacterial cellulose show promise as biodegradable coating materials.

9.4 Integration with Advanced Drug Delivery Systems

Combination of taste masking with targeted drug delivery creates multifunctional formulations addressing multiple therapeutic challenges [36]. Nano-enabled taste masking systems simultaneously provide improved bioavailability, controlled release, and palatability. Smart polymers responding to multiple stimuli (pH, temperature, enzymes) enable sophisticated control over taste masking and drug release. Biomimetic approaches inspired by natural systems, such as protein corona formation and mucosal adhesion, inform design of novel taste masking strategies.

Integration of taste masking in continuous manufacturing processes requires development of in-line quality control methods and real-time release testing. Combination products incorporating devices with taste-masked formulations, such as smart pills with electronic monitoring, represent emerging opportunities. Long-acting injectable formulations with taste-masked oral loading doses address adherence challenges in chronic disease management. Cell-based delivery systems encapsulating drugs within engineered cells provide ultimate taste masking through biological barriers.

10. Conclusion

The field of pharmaceutical taste masking has evolved remarkably from simple flavoring approaches to sophisticated technologies addressing the molecular basis of drug-induced bitter taste. Current innovations spanning physical barriers, molecular complexation, chemical modifications, and nanotechnology provide

formulators with a comprehensive toolkit for developing palatable medications. The successful commercialization of numerous taste-masked products demonstrates the practical implementation and clinical value of these technologies.

Future success in taste masking will be driven by convergence of multiple disciplines including pharmaceutical sciences, sensory biology, materials science, and digital technology. The integration of artificial intelligence and machine learning promises to accelerate formulation development through predictive modeling and optimization. Personalized medicine approaches based on genetic variations in taste perception will enable tailored taste masking strategies for individual patients. Sustainable technologies using bio-based materials address environmental concerns while maintaining effectiveness.

As regulatory agencies continue emphasizing patient-centric drug development, particularly for pediatric and geriatric populations, taste masking will remain critical for ensuring medication adherence and therapeutic success. The emergence of novel technologies such as 3D printing, advanced nanotechnology platforms, and smart delivery systems offers exciting opportunities for next-generation taste-masked formulations. Continued innovation in this field will ultimately improve patient outcomes through enhanced medication acceptability and adherence.

References

1. Mennella JA, Roberts KM, Mathew PS, Lukasewycz LD. Children's perceptions about medicines: individual differences and taste. *BMC Pediatr.* 2015;15:130.
2. Walsh J, Cram A, Woertz K, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. *Adv Drug Deliv Rev.* 2014;73:14-33.
3. Chandrashekar J, Mueller KL, Hoon MA, et al. T2Rs function as bitter taste receptors. *Cell.* 2000;100(6):703-711.
4. Meyerhof W, Batram C, Kuhn C, et al. The molecular receptive ranges of human TAS2R bitter taste receptors. *Chem Senses.* 2010;35(2):157-170.
5. Dagan-Wiener A, Di Pizio A, Nissim I, et al. BitterDB: taste ligands and receptors database in 2019. *Nucleic Acids Res.* 2019;47:D1179-D1185.
6. Zhang Y, Hoon MA, Chandrashekar J, et al. Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways. *Cell.* 2003;112(3):293-301.
7. Roland WS, Gouka RJ, Gruppen H, et al. 6-Methoxyflavanones as bitter taste receptor blockers for hTAS2R39. *PLoS One.* 2014;9(4):e94451.
8. Jaggupilli A, Howard R, Upadhyaya JD, et al. Bitter taste receptors: Novel insights into the biochemistry and pharmacology. *Int J Biochem Cell Biol.* 2016;77:184-196.
9. Margolskee RF. Molecular mechanisms of bitter and sweet taste transduction. *J Biol Chem.* 2002;277(1):1-4.
10. Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation. *Expert Opin Drug Deliv.* 2013;10(1):131-149.
11. Rosiaux Y, Jannin V, Hughes S, Marchaud D. Solid lipid excipients - matrix agents for sustained drug delivery. *J Control Release.* 2014;188:18-30.
12. Leopold CS, Eikeler D. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD). *J Drug Target.* 1998;6(2):85-94.
13. Timilsena YP, Akanbi TO, Khalid N, et al. Complex coacervation: Principles, mechanisms and applications in microencapsulation. *Int J Biol Macromol.* 2019;121:1276-1286.

14. Jones DM, Percel PJ. Coating of multiparticulates using molten materials: formulation and process considerations. In: *Multiparticulate Oral Drug Delivery*. Marcel Dekker; 1994:113-142.
15. Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. *Adv Colloid Interface Sci*. 2015;223:40-54.
16. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. *J Pharm Pharmacol*. 2010;62(11):1607-1621.
17. Anand V, Kataria M, Kukkar V, et al. The latest trends in the taste assessment of pharmaceuticals. *Drug Discov Today*. 2007;12(5-6):257-265.
18. Abu-Dief AM, Mohamed IMA. A review on versatile applications of transition metal complexes incorporating Schiff bases. *Beni-Suef Univ J Basic Appl Sci*. 2015;4(2):119-133.
19. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. *Nat Rev Drug Discov*. 2008;7(3):255-270.
20. Serajuddin ATM. Salt formation to improve drug solubility. *Adv Drug Deliv Rev*. 2007;59(7):603-616.
21. Coupland JN, Hayes JE. Physical approaches to masking bitter taste: lessons from food and pharmaceuticals. *Pharm Res*. 2014;31(11):2921-2939.
22. Slack JP, Brockhoff A, Batram C, et al. Modulation of bitter taste perception by a small molecule hTAS2R antagonist. *Curr Biol*. 2010;20(12):1104-1109.
23. Running CA. High false positive rates in common sensory threshold tests. *Atten Percept Psychophys*. 2015;77(2):692-700.
24. Trenfield SJ, Awad A, Goyanes A, et al. 3D printing pharmaceuticals: drug development to frontline care. *Trends Pharmacol Sci*. 2018;39(5):440-451.
25. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, et al. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. *Nanomedicine*. 2016;12(1):143-161.
26. Zielińska A, Ferreira NR, Durazzo A, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. *Molecules*. 2020;25(16):3731.
27. Luraghi A, Peri F, Moroni L. Electrospinning for drug delivery applications: A review. *J Control Release*. 2021;334:463-484.
28. Slavkova M, Breitzkreutz J. Orodispersible drug formulations for children and elderly. *Eur J Pharm Sci*. 2015;75:2-9.
29. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. *J Control Release*. 2011;153(2):106-116.
30. Stone H, Bleibaum RN, Thomas HA. *Sensory evaluation practices*. 4th ed. Academic Press; 2012.
31. Wasilewski T, Kamysz W, Gębicki J. Bioelectronic tongue: Current status and perspectives. *Biosens Bioelectron*. 2020;150:111923.
32. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. *AAPS J*. 2010;12(3):397-406.
33. Yang Y, Ye Z, Su Y, et al. Deep learning for in vitro prediction of pharmaceutical formulations. *Acta Pharm Sin B*. 2019;9(1):177-185.

34. Reed DR, Knaapila M. Genetics of taste and smell: poisons and pleasures. *Prog Mol Biol Transl Sci.* 2010;94:213-240.
35. George A, Shah PA, Shrivastav PS. Natural biodegradable polymers based nano-formulations for drug delivery: A review. *Int J Pharm.* 2019;561:244-264.
36. Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. *J Am Chem Soc.* 2016;138(3):704-717.
37. Liu F, Ranmal S, Batchelor HK, et al. Patient-centered pharmaceutical design to improve acceptability of medicines. *Int J Pharm.* 2014;460(2):424-435.
38. Pein M, Preis M, Eckert C, Kiene FE. Taste-masking assessment of solid oral dosage forms. *Int J Pharm.* 2014;465(1-2):239-254.
39. Hu X, Stanton R, Cui L, et al. Development of a new coprocessed excipient for direct compression. *Drug Dev Ind Pharm.* 2020;46(11):1847-1855.
40. Gittings S, Turnbull N, Roberts CJ, Gershkovich P. Dissolution methodology for taste masked oral dosage forms. *J Control Release.* 2014;173:32-42.
41. Keating AV, Soto J, Tuleu C, et al. Solid state characterisation and compaction behaviour of pharmaceutical excipient chitosan. *Int J Pharm.* 2018;536(1):467-477.
42. Samprasit W, Akkaramongkolporn P, Ngawhirunpat T, et al. Fast releasing oral electrospun PVP/CD nanofiber mats. *Int J Pharm.* 2015;492(1-2):233-242.
43. Preis M, Pein M, Breitzkreutz J. Development of a taste-masked orodispersible film containing dimenhydrinate. *Pharmaceutics.* 2012;4(4):551-562.
44. Amelian A, Wasilewska K, Wesoly M, et al. Taste-masking assessment of orally disintegrating tablets and lyophilisates. *Saudi Pharm J.* 2017;25(8):1144-1150.
45. Maniruzzaman M, Boateng JS, Snowden MJ, Douroumis D. A review of hot-melt extrusion: process technology to pharmaceutical products. *ISRN Pharm.* 2012;2012:436763.